CYP2C9 and VKORC1 genetic polymorphism analysis might be necessary in patients with factor V Leiden and prothrombin gene G2021A mutation(s)

Diagnostic Molecular Pathology

Volumn 16, Issue 3, 2007, Pages 184-186

  Leung, Allen ^a   Huang, Chih Kang ^a   Muto, Riho ^a   Liu, Yinxian ^a   Pan, Qiulu ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

CYP2C9; Factor V Leiden; Prothrombin gene mutation; VKORC1; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CYTOCHROME P450 2C9; PROTEIN G20210A; PROTHROMBIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG; WARFARIN;

ALLELE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA POLYMORPHISM; GENE MUTATION; GENETIC ANALYSIS; GENOTYPE; HUMAN; PRIORITY JOURNAL; RISK FACTOR; VENOUS THROMBOEMBOLISM;

ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION DISORDERS, INHERITED; FACTOR V; HUMANS; MIXED FUNCTION OXYGENASES; MUTATION; POLYMORPHISM, GENETIC; PROTHROMBIN; WARFARIN;

EID: 34548216413     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e3180467811     Document Type: Article

References (16)

1. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-463.
2. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med. 1998;158:585-593.
3. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost. 1999;82:610-619.
4. Bertina RM, Rosendaal FR. Venous thrombosis - the interaction of genes and environment. N Engl J Med. 1998;338:1840-1841.
5. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA. 1993; 90:1004-1008.
6. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood. 1996;88:3698-3703.
7. Rosendaal FR, Koster T, Vandenbroucke JP, et al. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood. 1995;85:1504-1508.
8. Torn M, Bollen WLEM, van der Meer FLM, et al. Risks of oral anticoagulant therapy with increasing age. Arch Intern Med. 2005;165:1527-1532.
9. Sconce EA, Khan TI, Wynne HA, et al. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristic upon warfarin dose requirements: proposal for a new dosing regimen. Blood. 2005;106:2329-2333.
10. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Imparied (S)-warfarin metabolism catalysed by the R144C varient of CYP2C9. Pharmacogentics. 1994;4:39-42.
11. Haining RL, Hunter AP, Veronese ME, et al. Alleles variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate steroselectivity, and prochiral selectivity of the wodle-type and I359L mutant forms. Arch Biochem Biophys. 1996;333:447-458.
12. Kamali F. Genetic influences on the responses to warfarin. Curr Opin Hematol. 2006;13:357-361.
13. Xie HG, Pasad HC, Kim RB, et al. CYP2C9 allelic variants: ethnic distribution and functional significance. Adv Drug Deliv Rev. 2002; 54:1257-1270.
14. Geisen C, Watzka M, Sittinger K, et al. VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thromb Haemost. 2005;94:773-779.
15. Montes R, Ruiz de Gaona E, Martinez-Gonzatez MA, et al. The c.-1639G > A polymorphism of the VKORC1 gene is a major determinant of the response to acenocoumarol in anticoagulated patients. Br J Hematol. 2006;133:183-197.
16. Kamari F, Khan TI, King BM, et al. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmcol Ther. 2004;75:204-212.